Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

Pinkal Desai, Zichan Li, Ying Li, Nuria Mencia-Trinchant, Kathryn Gorski, Wodan Ling, Ellen Ritchie, Michael Samuel, Jonathan Canaani, Michal Bar-Natan, Olivier Elemento, Lesley Tinker, Wendy Cozen, Monica Guzman, Andrea Sboner, Gail Roboz

Blood (2025) 146 (Supplement 1): 1399.

https://doi.org/10.1182/blood-2025-1399

Published: 2025

Journal Articles

Disease characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) involvement

Michal Bar-Natan, Sarra Yekta, Justin Kaner, Jonathan Canaani, Pinkal Desai, Ellen Ritchie, Michael Samuel, Hannah Levavi, Eshani Pareek, Debra D'Angelo, Gail Roboz

Blood (2025) 146 (Supplement 1): 1557.

https://doi.org/10.1182/blood-2025-1557

Published: 2025

Journal Articles

Access to acute promyelocytic leukemia treatment in New York City

Blood (2025) 146 (Supplement 1): 6205.

https://doi.org/10.1182/blood-2025-6205

Published: 2025

Journal Articles

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Blood (2025) 146 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2025-1737

Published: 2025

Journal Articles

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Blood (2025) 146 (Supplement 1): 344.

https://doi.org/10.1182/blood-2025-344

Published: 2025

Journal Articles

Transfusion burden during the initial induction Phase in Acute Myeloid Leukemia is tightly associated with treatment intensity

Jonathan Canaani, Sarra Yekta, John-William Sidhom, Justin Kaner, Ellen Ritchie, Michal Bar-Natan, Michael Samuel, Pinkal Desai, Gail Roboz

Blood (2025) 146 (Supplement 1): 5172.

https://doi.org/10.1182/blood-2025-5172

Published: 2025

Journal Articles

How I use maintenance therapy in acute myeloid leukemia

Gail J. Roboz, Jonathan Canaani

Blood (2025) 145 (12): 1273–1281.

https://doi.org/10.1182/blood.2024024010

Published: 2025

Journal Articles

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Gail J. Roboz, Nuria Mencia-Trinchant, Gabriela Pereira, Ellen K. Ritchie, Justin D. Kaner, Michael Samuel, Michal Bar-Natan, Jonathan Canaani, Sharmaine Griffith-Baker, Pinkal Desai, Monica L Guzman

Blood (2024) 144 (Supplement 1): 1576.

https://doi.org/10.1182/blood-2024-212090

Published: 2024

Journal Articles

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Blood (2024) 144 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2024-210134

Published: 2024

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Justin Grenet, Neela Easwar, Akriti G. Jain, Madelyn Burkart, Xiaoyue Ma, Paul Christos, Ellen K. Ritchie, Michael Samuel, Justin D. Kaner, Jonathan Canaani, Aaron D. Goldberg, Shira N. Dinner, Kendra L. Sweet, Gail J. Roboz, Pinkal Desai

Blood (2024) 144 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2024-206340

Published: 2024

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Journal Articles

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Blood (2022) 140 (Supplement 1): 6162–6164.

https://doi.org/10.1182/blood-2022-163020

Published: 2022

Journal Articles

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Cristina Papayannidis, Blanca Boluda, Jonathan Canaani, Pascal Turlure, Ann De Becker, Anand Tandra, Dina Elsouda, Arnaud Houweling, Anil Upadhyay, Isabelle Wouters, Paresh Vyas

Blood (2022) 140 (Supplement 1): 11641–11643.

https://doi.org/10.1182/blood-2022-156296

Published: 2022

Journal Articles

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

Liron Miller, Mor Freed-Freundlich, Tamer Hellou, Avichai Shimoni, Abraham Avigdor, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 5717–5718.

https://doi.org/10.1182/blood-2022-156096

Published: 2022

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival

Tamer Hellou, Omri Cohen, Abraham Avigdor, Avichai Shimoni, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 3229–3230.

https://doi.org/10.1182/blood-2022-156099

Published: 2022

Journal Articles

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

Gal Sharvit, Gabriel Heering, Maya Zlotnick, Arnon Nagler, Abraham Avigdor, Avichai Shimoni, Jonathan Canaani

Blood (2021) 138 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2021-145552

Published: 2021

Journal Articles

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

Naama Keren Froim, Gabriel Heering, Gal Sharvit, Maya Zlotnick, Arnon Nagler, Avichai Shimoni, Abraham Avigdor, Jonathan Canaani

Blood (2021) 138 (Supplement 1): 3392.

https://doi.org/10.1182/blood-2021-145551

Published: 2021

Journal Articles

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

Ofir Wolach, Itai Levi, David Lavie, Jonathan Canaani, Sigal Tavor, Ilana Hellmann, Tamar Tadmor, Tsila Zuckerman, Galia Stemer, Jenia Berelovich, Keren Ofek, Neta Frankel, Moshe Grunspan, Yishai Ofran, Yakir Moshe

Blood (2021) 138 (Supplement 1): 1246.

https://doi.org/10.1182/blood-2021-147245

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

Disease characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) involvement

Access to acute promyelocytic leukemia treatment in New York City

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Transfusion burden during the initial induction Phase in Acute Myeloid Leukemia is tightly associated with treatment intensity

How I use maintenance therapy in acute myeloid leukemia

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only